Current projects

We encourage prospective D/P's (donor/participants) to become involved in current and future studies. If a study listed does not apply to your particular situation we still invite you to register so that we may include you in our database and contact you for future studies.

We are looking for D/P's in the following categories:

ID # Required D/P's Enrolled D/P's Remaining D/P's Inclusion Criteria
308929 1 1 0 Monkeypox Positive Serum Samples from Inventory
308911 20 20 0 Plasma from Healthy Donors with High Platelet count
308825 10 0 10 K2EDTA Plasma from Healthy Donors
308819 12 0 12 Fresh Whole Blood Collection from HxV Negative Donors TZC0012905/SRF_0002888
308362 5 4 1 Pre-Selected Treponema pallidum Positive Urine Samples from Inventory_ENQ261022-2
307884 50 0 50 Prospective Whole Blood Collection with Specific HbA1c level TZC0031646
307874 6 6 0 Pre-Selected HBV Samples with Viral Load ,W Africa or SE Asia regions_TZC0040382/SRF_0003101
307094 5000 101 4899 Pre-Selected HCV Positive Samples from Inventory
307093 5000 97 4903 Pre-Selected HIV Positive Samples from Inventory
306316 1 1 0 Normal CP2D unit from Inventory
305552 1000 11 989 Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections - Miami
305335 5000 106 4894 SCF Samples from Inventory_TZC0034383
304467 5000 2525 2475 Pre-Selected HxV Negative Samples from Inventory (SRF_0002985)
304325 23 22 1 Pre-Selected Covid Positive samples from Inventory (Dry Swabs)
304301 14 12 2 Pre-Selected HBV Samples with Viral Load , collected in Europe, W Africa or SE Asia regions
304222 230 236 -6 Whole Blood Units from HxV Negative Donors
303905 6 0 6 Fresh Whole Blood Collection from HxV Negative Donors_TZC0037344/SRF_0003079
303578 50 50 0 Pre-Selected HCV Positive samples from Inventory
303479 50 12 38 Prospective Collections from HCV Positive Population
303281 52 18 34 Pre-Selected TV Positive Samples from Inventory.
303208 9 0 9 Prospective Whole Blood Collection from HxV Negative Donors
303194 6 6 0 Prospective Whole Blood Collection from HxV Negative Donors
303165 80 0 80 Prospective Rectal Swab Collection
302961 3 3 0 Prospective Whole Blood Collection from HxV Negative Donors (Paxgene ccfDNA tubes)
302957 24 24 0 Female Vaginal Sample Collection Protocol for Panel Development
302880 97 0 97 Pre-Selected HIV Samples from Inventory (Project# Feasibility HIV, HCV inclusivity_BCW)
302879 102 0 102 Pre-Selected HCV Samples from Inventory (Project# Feasibility HIV, HCV inclusivity_BCW)
302539 3 0 3 Pre-Selected Monkeypox Positive Samples from Inventory
302289 100 39 61 Prospective Lesion Swab Collection TZC0023314/SRF_0002965
302109 10 6 4 Pre-Selected Monkeypox Positive Samples from Inventory
301909 800 346 454 Abbott RealTime CT/NG Testing, Cepheid_248C
301558 38 20 18 Pre-Selected Syphilis Samples from Inventory (Aditional Volume)
300305 745 661 84 Pre-Selected HBV Plasma Samples from Inventory (Project# HDV HBV RNA_BCW)
299980 25 25 0 Pre-Selected Urine Negative (CT/GC/Trich) Samples from Inventory
299978 25 24 1 Pre-Selected HxV Negative Serum Samples from Inventory
299865 30 1 29 Nasal Collection Protocol for Flu A/FluB positive donors
299263 650 598 52 VZV IgG Testing on LIAISON XL_DiaSorin the 6000 Series
299262 60 63 -3 DBS Cards and Serum from Syphilis Positive and Negative Donors
299261 60 86 -26 DBS Cards and Serum from HSV2 Positive and Negative Donors
299260 60 93 -33 DBS Cards and Serum from HCV Positive and Negative Donors
299259 80 82 -2 DBS Cards and Serum from HIV Positive and Negative Donors
299254 60 95 -35 Cervical and Vaginal Swabs from HPV Positive and Negative Donors
298305 10 5 5 Prospective Lesion Swab, Oropharyngeal Swab and Whole Blood Collection from Positives Monkeypox Donors
298178 300 19 281 Prospective Lesion Swabs Collection from Suspected Monkeypox Donors_SRF_2981
297859 25 7 18 Prospective Whole Blood and PBMCs collected from Healthy Females (selected age, race and ethnicity)
297190 50 31 19 Pre-Selected HIV AB Positive and PCR Negative Samples from Inventory
296225 34 34 0 Pre-Selected HBV Plasma Samples from Inventory
296060 900 0 900 1. Mild or moderate nasal congestion and/or rhinorrhea without other symptoms
2. Treatment with systemic antibiotic, antiviral, or antifungal agents within the past 7 days of presentation EXCEPT:
a. Use of topical antibiotic, antiviral, or antifungal agents
b. Use of peri-operative (prophylactic) antibiotics
c. Receipt of antibiotics/antivirals during the enrollment visit
d. Ongoing antiviral treatment or prophylaxis for HIV or hepatitis B or hepatitis C, or herpes prophylaxis
3. Treatment with interferon therapy, intravenous immunoglobulin (IVIG), or a live viral immunization (e.g., rotavirus, varicella, MMR, nasal influenza, etc.) within the past 15 days
4. Participants unlikely to be available for follow-up within the study period, e.g., moving away from the clinic area, no phone.
5. Participants unable or unwilling to produce all required study samples
6. Previously enrolled in the current study
294344 100 22 78 Prospective Collection for subjects suspected to be positive for Monkeypox
294235 110 110 0 Pre-Selected Plasma Samples from Healthy Donors Collected Prior to 2018
293753 60 13 47 Female Vaginal Sample Collection Protocol for CT/GC positive donors
293648 30 4 26 Prospective Collection for subjects with CoV-2, Flu A, Flu B, RSV
292896 10 5 5 Prospective Serum Collection Protocol from RPR Positive Subjects
292590 10000 0 10000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain Nasal Swab, Pharyngeal Swab, Vaginal Swab, Rectal Swab, Lesion Swab, Saliva Sample and/or Blood Samples from a positive or suspected positive D/Ps with Monkeypox
292576 20 21 -1 Prospective Collection of SARS-CoV-2 Positive NP Samples
292415 30 19 11 Pre-Selected Gonorrhea Positive Samples from Inventory (Urine)
291821 200 72 128 Pre-Selected HBsAg Samples with Viral Load from Inventory
291489 10 10 0 Pre-Selected RPR Positive Samples from Inventory with Specific Titer
289663 5 0 5 Pre-Selected HBsAg Positive Samples with Viral Load from Inventory
287443 4 0 4 HxV Negative Pooled K3EDTA Plasma from Inventory - TZC0022637/ SRF_0002958
285982 50 50 0 Pre-Selected Samples from D/Ps with High Risk for STD Infection (MSM Population)
284336 200 10 190 Pre-Selected HCV Positive Samples from Inventory (19SUST056)
283651 50 0 50 Fresh Whole Blood from HIV-1 Positive Individuals
283190 200 113 87 Protocol No. LIA-STI-250 - cobas CT/NG/MG Nucleic acid test for use on the cobas Liat System: Feasibility Performance Evaluation
283000 8 5 3 Pre-Selected HCV Positive Samples from Inventory with HCV Viral Load and Genotype
282948 100 23 77 Nasal and Nasopharyngeal swabs from SARS-CoV-2 (Omicron) Positive Donors
282803 5 4 1 Fresh Whole Blood from HIV-1 Positive Individuals
282613 100 0 100 Rapigen-001 - Clinical Study Protocol - BIOCREDIT COVID-19 Ag Home Test Nasal (Puerto Rico)
282612 100 75 25 Rapigen-001 - Clinical Study Protocol - BIOCREDIT COVID-19 Ag Home Test Nasal (Miami)
282610 10000 0 10000 A Multi Site, Longitudinal, Prospective Sample Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
281873 30 3 27 Pre-Selected Gonorrhea Positive Samples from Inventory (Urine)
281868 30 3 27 Pre-Selected Chlamydia Positive Samples from Inventory (Urine)
281776 200 205 -5 Oropharyngeal Swabs from Healthy Donors
281675 20000 2904 17096 Customer Samples kept in Biorepository (CHIV Study 2011, Universiti of Miami, Zawadzki, Cassandra )
281523 50 50 0 Prospective Whole Blood Collection from HxV Negative donors (Age 60+)
281517 7 7 0 Normal Healthy DP's collected in Whole Blood with Specific WBC Count - SRF_0002902
- 1 donor with WBC Count 3,000-5,000/uL
- 1 donor with WBC Count 5,000-6,000/uL
- 4 donor with WBC Count 9,000-10,000/uL
- 1 donor with WBC Count 11,000-14,000/uL
281243 25 25 0 Pre-Selected HIV-2 Samples from Inventory
280543 6 2 4 Pre-Selected HIV and HCV Positive Plasma Samples from Inventory with High Viral Load
278976 100 112 -12 Prospective Sars-Cov-2 , Flu A, Flu B and RSV Samples Collection_TCZ0006755 / SRF_0002812
277324 30 14 16 Pre-Selected RPR Positive Samples from Inventory
276588 6 6 0 RMS SARS-CoV-2 Samples for Heat Inactivation
276033 200 187 13 Collection protocol for Panel construction (Custom HIV-1 panels, Q_16975)
272609 5 1 4 HIV-1 Positive Prospective Blood Collection Protocol
- 2 D/Ps with Viral Load over 2,000 cp/mL
- 1 D/P with Viral Load at around 1,000 cp/mL
- 1 D/P with Viral Load at around 2,000 cp/mL
- 1 D/P with Viral Load at around 3,000 cp/mL
272143 400 0 400 Pre-Selected HBV Positive Samples from Inventory with Viral Load and Genotype
271914 100 8 92 COVID-19 Testing; Private Office
271841 25 17 8 Pre-Selected anti-HBs Samples from Inventory
271463 800 0 800 Protocol: LIA-CoV-560 - cobas SARS-CoV-2 and cobas SARS-CoV-2 & Influenza A/B Nucleic acid tests for use on the cobas Liat® System: Clinical Performance Evaluation - Las Vegas
271462 800 0 800 Protocol: LIA-CoV-560 - cobas SARS-CoV-2 and cobas SARS-CoV-2 & Influenza A/B Nucleic acid tests for use on the cobas Liat® System: Clinical Performance Evaluation - Northridge
267417 50 46 4 Prescreaning collection for JR 236653 (HIV Positive DPs, Viral Load 1000-8000)
267180 1500 955 545 Prospective Healthy Subject Blood Collection Protocol
266931 120 17 103 PAS-19SUST053 Testing HBV VL (Abbott & Hologic)
266866 120 26 94 Protocol: FD-001 - Clinical Evaluation of the Fosun COVID-19 Ag Home Test In Symptomatic and Asymptomatic Subjects
261154 800 1892 -1092 Protocol: LIA-CoV-560 - cobas SARS-CoV-2 and cobas SARS-CoV-2 & Influenza A/B Nucleic acid tests for use on the cobas Liat® System: Clinical Performance Evaluation
259067 100 50 50 Clinical Evaluation of the Visby Medical Respiratory Health Test for the Detection and Differentiation of SARS-CoV-2, Influenza A and Influenza B Viral RNA - Clinical Protocol TP-000547
251350 100 30 70 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
243774 60 0 60 Pre-Selected BKV and EBV Negative Plasma Samples from Inventory - SRF_0002565
243767 450 0 450 Pre-Selected BKV and EBV Positive Plasma and Urine Samples from Inventory - SRF_0002565
242729 300 299 1 Vaginal Sample Collection Protocol - Donors with Vaginitis Symptoms
242206 5000 27164 -22164 COVID-19 Testing
239188 500 0 500 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
236653 5 2 3 HIV-1 Positive Prospective Blood Collection Protocol
- 2 D/Ps with Viral Load over 2,000 cp/mL
- 1 D/P with Viral Load at around 1,000 cp/mL
- 1 D/P with Viral Load at around 2,000 cp/mL
- 1 D/P with Viral Load at around 3,000 cp/mL
233218 150 8 142 IDS-21MAXCOMBO - SARS-CoV-2 Hologic Aptima Testing
231203 100 103 -3 Clinical Evaluation of Visby Medical Personal PCR Women’s Sexual Health Test for the Detection of CT, GC and TV using self-collected Vaginal Swabs - Protocol TP-000669
231202 53 53 0 Beta Study of the Visby Sexual Health Test - Clinical Protocol TP-000516
230530 20000 1295 18705 Customer Samples kept in Biorepository (CMVG Samples, Susan Rimpel)
228548 100 102 -2 Remnant VZV Samples (IGG Negative)
228201 20000 466 19534 Customer Samples kept in Biorepository from Minneapolis Medical Research Foundation (MMRF)
227994 130 5 125 PAS-19SUST054 - HCV
227993 130 1 129 PAS-19SUST052 - HBV
227992 130 10 120 PAS-18SUST041 - Evaluation of the BD Vacutainer® K2EDTA Blood Collection Tubes with Hemogard™ Closure using Molecular Diagnostic Testing for HIV-1 Viral Load (VL) Assay
226001 100 39 61 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
225611 10000 0 10000 A Multi Site, Longitudinal, Prospective Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
225101 1000 9 991 COVID-19 Testing; Private Office
224701 360 0 360 cX8-COV-549: Classic Repro Protocol
224514 600 76 524 Initiative to Screen Potential Study Candidates (SUST)
219607 1000 13 987 COVID-19 Testing; Private Office
213622 2500 0 2500 Protocol: cX8-CAB-547 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study
210071 2500 555 1945 Protocol: cX8-CAB-533 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study
208168 1000 111 889 COVID-19 Testing; Private Office
201758 130 48 82 PAS-18SUST033 - Validation of the Clinical Performance of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure in Comparison with the Greiner Vacuette® K2EDTA Gel Tubes for Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay
200508 1000 60 940 COVID-19 Testing; Private Office
198391 500 0 500 Prospective Healthy Subject Blood Collection Protocol
195775 20000 1380 18620 Customer Samples kept in Biorepository from HBcT2 [JRID#93116]
190737 5000 40 4960 SARS-CoV-2 Survey (PT)
184026 700 542 158 SARS-CoV-2 RNA Hologic Testing
182696 1000 355 645 Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections
178076 130 79 51 PAS -19SUST046 - Evaluation of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure for Repeatability and Reproducibility of Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay
175792 10000 116 9884 COVID-19 Testing; Tu Cara me Sue
175398 10000 552 9448 COVID-19 Testing; Crew-Royal Caribbean Cruises Ltd
175121 1000 27 973 CBC Initiative
174026 1000 122 878 COVID-19 Testing; Private Office
173768 10000 0 10000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain Saliva, Sputum, Nasal, Pharyngeal, Blood and/or Finger Stick Specimens from SARS-CoV-2 positive subjects
173505 20 20 0 SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory
172886 1000 1018 -18 COVID-19 Testing; Private Office
169711 400 398 2 SARS-CoV-2, Nasal swab, Nasopharyngeal Swab, Oropharyngeal swab and Saliva
169440 300 110 190 Remnant Pregnancy Samples
169439 100 258 -158 Remnant HSV Samples
168867 1000 350 650 COVID-19 Testing; Private Office
168078 50 2 48 Prospective COVID-19 Positive Sample Collection Protocol (NPS and Raw Saliva)
165868 1000 156 844 COVID-19 Testing; Private Office
163904 1000 1002 -2 COVID-19 Testing; Private Office
155679 30 313 -283 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
154904 10000 40 9960 COVID-19 Testing; Private Office
154536 1000 458 542 Cerebral Spinal Fluid (CSF) Unit from Live D/Ps
- Minimum total volume of 500 ml required
- Individual samples of at least 0.25 ml
- The samples must have no trace of hemolysis (red color).
- Stored under -80°C.
- Remnant material acceptable
- No IRB nor Informed Consent needed
- No clinical history
- Custom Manifest file
153900 10000 31301 -21301 COVID-19 Testing, Florida Department of Health
152854 10000 0 10000 A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
152825 5000 106651 -101651 COVID-19 Testing
152672 5000 40 4960 Follow-UP_COVID-19 Testing_Blood and Nasopharyngeal Swabs
152331 5000 1654 3346 COVID-19 Testing
151681 5000 3 4997 Refer to Processing Instructions @ Attachment Tab
151476 1 0 1 HIV Group and Subtype Testing
149547 5000 240 4760 Refer to Processing Instructions @ Attachment Tab
TESTS TO SELECT PER LOCATION - REFER TO ATTACHMENT TAB
148791 5000 36 4964 Refer to Processing Instructions @ Attachment Tab
145574 5000 90 4910 Refer to Processing Instructions @ Attachment Tab
144620 5000 47 4953 Refer to Processing Instructions @ Attachment Tab
144001 100 825 -725 Pediatric EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM):
- 50 samples from subjects with the ages of 2 through 12 years of age AND
- 50 samples from subjects with the ages of 13 through 21 years of age
- Gender: Male or Female
- Minimum Volume: 1.5 mL (1.2 mL's)
- Storage Temperature: Samples must have been frozen at -20°C or below within 2 days of collection.
143401 1500 1158 342 Cerebral Spinal Fluid (CSF) Unit from Live D/Ps
- Minimum total volume of 3000 ml required
- Individual samples of at least 0.25 ml
- The samples must have no trace of hemolysis (red color).
- Stored under -80°C.
- Remnant material acceptable
- No IRB nor Informed Consent needed
- No clinical history
- Custom Manifest file
142755 5000 100 4900 Refer to Processing Instructions @ Attachment Tab
141914 1000 7 993 HIV Initiative
141493 5000 50 4950 HCV Viral Load and Genotype Survey (PT)
141491 5000 21 4979 HBV Viral Load Survey (PT)
141490 5000 50 4950 HIV Viral Load Survey (PT)
140923 5000 90 4910 Refer to Processing Instructions @ Attachment Tab
140922 5000 50 4950 Refer to Processing Instructions @ Attachment Tab
140530 5000 10 4990 Rubella IgG (AAB - PT)
140528 5000 6 4994 ToRCH (AAB - PT)
139409 5000 105 4895 Pregnancy (PT)
137933 5000 0 5000 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon
137683 930 235 695 Preeclampsia Blood Collection Protocol from Asymptomatic and Symptomatic Populations
136025 300 357 -57 EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM)
134182 100 80 20 HBV/Mayaro Samples from Colombia
133225 200 274 -74 Prospective HCV Positive serum collection
129688 200 163 37 EBV / EBK Samples from National Center of Urology - Tbilisi, Georgia
129538 1000 309 691 RPR Initiative
128402 1000 64 936 CBC Initiative
124266 5000 143 4857 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cote D'Ivoire
122931 5000 2334 2666 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
122654 5000 171 4829 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Swaziland
120851 140 26 114 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
120409 300 84 216 Matched Prospective Collection Protocol from an HCV, HBsAg and/or RPR Positive Reactive Population
109382 100 32 68 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV
109381 300 6 294 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
108692 1000 992 8 HxV Testing Initiative
102772 50 26 24 Random Cadaveric Samples
102419 1000 454 546 Samples on hold for future shipments to China
98830 10000 0 10000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP, Endocervical Swab, Vaginal Swab, Nasal Swab, Pharyngeal Swab, Rectal Swab, Urethral Swab and/or Urine Samples
98084 1000 577 423 CBC Qualifying Job Request
96278 195 185 10 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
96055 40 1818 -1778 Hologic Panels for HIV and HCV
94841 500 1 499 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV - LGR
93116 700 755 -55 Prospective Blood Collection Protocol from D/Ps with Signs & Symptoms or at High Risk for Hepatitis
80997 5000 428 4572 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon
79734 100 0 100 Prospective Zika Screening and Longitudinal Sample Collection Protocol
78138 300 140 160 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
78137 300 414 -114 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV
74261 10000 0 10000 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
68258 10000 0 10000 A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
66495 200 225 -25 Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World for Dengue
63869 1 2 -1 Negative Material for Panel Member
63868 1000 555 445 Blinded HIV/HBV/HCV Prospective Blood Collection Protocol from Guinea Bissau
56717 20000 0 20000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP , Endocervical, Vaginal, Nasal and/or Urine Samples
55075 10000 28 9972 Beta HCG Matched Set Prospective Blood Collection Protocol
54664 200 148 52 Random Cadaveric Samples
38626 300 143 157 Prospective Sample Collection of Specifically Diagnosed D/Ps with Diseases of the Liver or Related Complications:
·50 x Alcoholic liver disease
·30 x Autoimmune hepatitis
·30 x Fatty liver disease
·30 x Non-alcoholic Steatohepatitis (NASH)
·30 x Primary Biliary Cirrhosis (PBC)
27615 15000 633 14367 Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World
26761 10000 482 9518 HIV Positive Time Stability Whole Blood Collection Protocol
10694 3000 2234 766 HCV Longitudinal Prospective Blood Collection Protocol
10693 3000 369 2631 HBV Multi-Point Prospective Blood Collection Protocol
8568 300 1648 -1348 Positive Plasma Units from Blood Centers Around the World (HIV, HBsAg & HCV)



BCW helps clinicians during their research process through collection sites and D/P availability. Our collection sites have been duly inspected and adhere to our Good Manufacturing Practices thus ensuring reliability during the collection process. In addition to this we provide training seminars as part of our Quality Assurance in order to maintain the level of quality that our customers are accustomed to.

You will be invited to participate in research studies for the advancement of diagnostic technologies. Participation in these studies is voluntary. Our D/P's are informed of what the research projects are about and are given an Informed Consent, which evidences their willingness to participate. In order to protect our D/P's we never divulge your identity to the research facilities thus guaranteeing D/P confidentiality.



Contact us to learn more